What safety precautions should you pay attention to before taking giritinib (segatan)?

Gilteritinib (Gilteritinib) is an oral FLT3 inhibitor, mainly used to treat patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML). Before starting to take giritinib, patients need to fully understand the relevant safety matters to ensure the safety of the medication and reduce the occurrence of adverse reactions.

Patients should undergo a comprehensive hematologic and organ function assessment before taking the drug. Giritinib may cause a decrease in platelets, white blood cells, and red blood cells, and may also have a certain impact on liver and kidney function. Therefore, before taking medication, it is necessary to measure blood routine, liver and kidney function and electrocardiogram to evaluate whether there are serious hematological abnormalities or organ damage to determine whether it is suitable to start medication.

Attention should be paid to concomitant medication use. Giritinib is mainly metabolized by CYP3A4. If the patient is taking strong CYP3A inhibitors or inducers, the blood concentration of the drug may be affected, thereby increasing toxicity or reducing efficacy. In addition, patients who are taking other anti-leukemia drugs, anticoagulants or drugs with a risk of prolonging the QT interval should also use them with caution and adjust the dose or monitor their electrocardiogram if necessary.

Geritinib is contraindicated in pregnant and lactating women because the drug may cause potential harm to the fetus or infant. During treatment, female patients need to take effective contraceptive measures, and male patients should also use contraceptive methods to prevent the drug from affecting reproductive health through sperm. At the same time, doctors should be informed of their past history of cardiovascular disease, bleeding tendencies, or other major chronic diseases before starting medication, so that doctors can comprehensively assess medication risks and formulate individualized safety plans.

Reference materials:https://www.drugs.com/

xa0